Tanja Bedke

TL;DR: It is reported that CD4+ T cells isolated from patients with IBD produce high levels of interleukin-22 binding protein (IL-22BP), the endogenous inhibitor of the tissue-protective cytokine IL-22, which suggests that anti–TNF-α therapy may act at least in part by suppressing IL- 22BP and point toward a more specific potential therapy for IBD.

TL;DR: It is reported that IL-10-producing CD4+ T cells are phenotypically and functionally heterogeneous and found that patients with Inflammatory Bowel Disease demonstrate a deficiency in this specific regulatory T-cell subpopulation.

TL;DR: It is shown that a population of IL-17 + IL-22 + , but not single IL- 22 + , CD4 + T cells are induced by TGF-β, enriched in patients with colorectal cancer (CRC) and drive CRC progression in mice.

TL;DR: A review of the recent findings on the heterogeneity of IL-10 producing T cells and their impact on the target cells and two possible explanations for the dual functions ofIL-10 are proposed.

TL;DR: IL-22BP plays a protective role in acute liver damage, via controlling IL-22–induced Cxcl10 expression, and neutralization of CXCL10 reversed the increased disease susceptibility of Il22bp-deficient mice.